Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch Services, Inc. Launches Stroke Patient Care Program

  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
New Products
09.09.2009
LifeWatch AG´s (SIX Swiss Exchange: LIFE) American subsidiary 
LifeWatch Services, Inc., the leading provider of wireless 
telemedicine services in the U.S., announced the launch of its Stroke
Patient Care program for monitoring patients who have experienced a 
Transient Ischemic Attacks(TIA)/Stroke of unknown origin 
(cryptogenic).
Stroke is the third leading cause of death in the United States. Each
year approximately 795,000 Americans will suffer a new or recurrent 
stroke, which on average, means that a stroke will occur every 40 
seconds. A Transient Ischemic Attack (TIA) is defined as a brief 
episode in which the brain gets insufficient blood supply and 
described as an incomplete stroke whose symptoms typically last for 
minutes up to a few hours. One third of individuals who have had one 
or more TIAs will suffer a stroke. With 36% of those who survive such
an event, the cause is unknown or cryptogenic.  Furthermore, multiple
clinical trials have demonstrated the efficacy of chronic oral 
anticoagulation (Coumadin) in patients who are at high risk for 
recurrent embolic neurological events. However, Coumadin is not 
without risk and requires accurate diagnosis of Paroxysmal Atrial 
Fibrillation (PAF) before the initiation of therapy. A recent study 
demonstrates that outpatient cardiac telemetry can detect 
asymptomatic (no symptoms) Atrial Fibrillation (AF) in up to 23% of 
patients who have experienced a stroke or TIA of unknown origin. AF 
episodes as brief as 30 seconds may indicate more prolonged and 
clinically significant AF.1 A specialized Stroke Patient Care program
utilizing LifeStar ACT technology to detect asymptomatic AF has the 
ability to accurately identify the cause of stroke and reduce the 
possibility of long term catastrophic effects.
"To significantly decrease the incidence of secondary stroke, 
physicians treating these patients need a convenient monitoring 
solution to identify stroke patients with abnormal heart rhythms but 
no symptoms", stated Leigh Ann Kelly, Vice President of Business 
Development at LifeWatch.  "LifeWatch´s Medical Advisory Board and 
senior clinicians have collaborated extensively with renowned stroke 
specialists and neurologists in order to develop a monitoring program
that meets the needs of both stroke patients and their treating 
physicians".
"Cryptogenic stroke is more common in the geriatric population, yet 
most cardiac event looping recorders present technological challenges
for these patients, in particular with those who have a neurologic 
deficit", stated Harry Kopelman, M.D., LifeWatch Medical Advisory 
Board Chairman. "The ACT III cardiac telemetry device is a better 
choice as a diagnostic tool with a dedicated disease management 
program, as it can lead to more accurate and efficient arrhythmia 
diagnosis which is critical to the management of the cryptogenic 
stroke population".
"The LifeWatch Stroke Patient Care program will be supported by the 
ACT service platform and is the second patient care program that we 
have launched in the past 18 months", stated Dr. Yacov Geva, Chairman
and CEO of LifeWatch AG, adding "This latest expansion will enable us
to pursue our mission of improving patient care and outcomes".
1. Tayal et al, Neurology 2008.
About LifeWatch AG LifeWatch AG, headquartered in Neuhausen am 
Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is 
the leading healthcare technology and solution company, specializing 
in advanced telehealth systems and wireless cardiac monitoring 
services. LifeWatch services treat high-risk and chronically ill 
patients, health conscious consumers and wellness programs. LifeWatch
has subsidiaries in the United States, the Netherlands, Japan, the 
United Kingdom, Switzerland and Israel. LifeWatch AG is the parent 
company of LifeWatch Services Inc., a leading US-based cardiac 
monitoring service provider, and manufacturer of telecardiology 
products. www.lifewatch.com
Sign-up for customized e-mail alerts and documentation requests is 
available at http://production.investis.com/lifewatch/alert-service/
This press release includes forward-looking statements. All 
statements other than statements of historical facts contained in 
this press release, including statements regarding future results of 
operations and financial position, business strategy and plans and 
objectives for future operations, are forward-looking statements. The
words "believe," "may," "will," "estimate," "continue," "anticipate,"
"intend," "expect" and similar expressions are intended to identify 
forward-looking statements. LifeWatch AG has based these forward 
looking statements largely on current expectations and projections 
about future events and financial trends that it believes may affect 
the financial condition, results of operations, business strategy, 
short term and long term business operations and objectives, and 
financial needs. These forward-looking statements are subject to a 
number of risks, uncertainties and assumptions. In light of these 
risks, uncertainties and assumptions, the forward-looking events and 
circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the 
forward-looking statements. All forward-looking statements are based 
only on data available to LifeWatch AG at the time of the issue of 
this press release. LifeWatch AG does not undertake any obligation to
update any forward-looking statements contained in this press release
as a result of new information, future events or otherwise.
THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF 
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR 
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS 
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN 
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH 
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE 
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN 
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE 
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. 
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY 
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG 
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED 
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL 
STATEMENTS OF THE ISSUER.

Further inquiry note:

For further information please contact:
Kobi Ben Efraim, Chief Financial Officer, LifeWatch AG
Tel +41 52 632 00 50 | Fax +41 52 632 00 51 | E-mail kobibe@lifewatch.com

Europe
Sensus Investor and Public Relations GmbH, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | E-mail lifewatch@sensus.ch

USA
Westwicke Partners
asher.dewhurst@westwicke.com

Branche: Healthcare Providers
ISIN: CH0012815459
WKN: 1281545
Index: SPI, SPIEX
Börsen: Frankfurt / Open Market / XETRA
SIX Swiss Exchange / Hauptsegment
Berlin / free trade

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG